TICKERNERD
Menu
DHDHHealthcare · Health Information Services

DH Stock Forecast: Definitive Healthcare Corp. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$1.04
0.00% on the day

The 8 Wall Street analysts covering Definitive Healthcare Corp. hold a median 12-month price target of $1.25 — +20.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$96.3M
Ticker Nerd rank
79 / 100
Median analyst target
$1.25
Analysts covering
8
Revenue$55.9M−5.5% y/y
Operating income−$4.8M
Net income−$192.4M
Free cash flow$8.4M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+27.8%
1M
+48.6%
YTD
−63.8%
1Y
−73.3%
From 52W high
−75.8%
From 52W low
+65.6%
$0.63
$4.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Definitive Healthcare Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Value
96
Issuance
76
Size
71
Revisions
65
Growth
54
Quality
42
Volatility
34
Momentum
15

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26DHHigh $3.00Median $1.25Low $0.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
1 Buy5 Hold2 Sell
Low $0.70Median $1.25High $3.00

The green dot is the last close — the median target sits +20.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026Morgan StanleyMaintainsEqual-Weight$2.50 → $1.50
29 June 2026B of A SecuritiesDowngradeUnderperform$3.50 → $0.70
29 June 2026B of A SecuritiesDowngradeUnderperform—
30 Mar 2026BarclaysMaintainsUnderweight—
27 Feb 2026Canaccord GenuityMaintainsHold—
27 Feb 2026Stephens & Co.MaintainsEqual-Weight—
9 Dec 2025BarclaysMaintainsUnderweight—
10 Nov 2025Canaccord GenuityMaintainsHold—
8 Aug 2025StifelMaintainsBuy—
12 May 2025Goldman SachsMaintainsNeutral—
4 Mar 2025Goldman SachsMaintainsNeutral—
3 Mar 2025BarclaysMaintainsUnderweight—
16 Jan 2025NeedhamReiteratesHold—
13 Jan 2025BarclaysDowngradeUnderweight—
20 Dec 2024Stephens & Co.InitiatesEqual-Weight—
8 Nov 2024NeedhamReiteratesHold—
17 Sept 2024BTIGInitiatesBuy—
9 Aug 2024Deutsche BankMaintainsHold—
7 Aug 2024BairdMaintainsNeutral—
7 Aug 2024BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Definitive Healthcare Corp. returned −73.3% against +21.4% for the S&P 500, dividends included.

DH vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26DHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+7.5%
Analysts raising
1
Analysts cutting
0
Fundamentals

Definitive Healthcare Corp. (DH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
0.4×

Cheaper than 85% of US stocks

Price / book
0.7×

Cheaper than 82% of US stocks

EV / EBITDA
3.5×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
−9.1%

Higher than 16% of US stocks

Earnings growth (YoY)
−5.5%

Higher than 29% of US stocks

Gross margin
74.5%

Higher than 87% of US stocks

Operating margin
−8.6%

Higher than 25% of US stocks

Net margin
−72.3%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−78.4%

Higher than 16% of US stocks

Return on assets
−1.9%

Higher than 37% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Definitive Healthcare Corp. (DH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Definitive Healthcare Corp. has a market value of $96.3M and an enterprise value of $122.8M.

  • Revenue in the twelve months to 31 Mar 2026: $238.3M. The latest quarter shrank 9.1% year on year.

  • Net income over the same four quarters: −$236.6M, a −99.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.62.

  • Free cash flow in the twelve months to 31 Mar 2026: $27.1M, after $12.2M of capital spending.

  • Definitive Healthcare Corp. spent $28.3M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 105.3M.

  • Trailing P/E: −0.7×; forward P/E: 4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Definitive Healthcare Corp. employs 678 people — $351K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 2 Sept 2026

Data provided by Twelve Data

Peers

DH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
DHDefinitive Healthcare Corp.$96.3M
79
LFMDLifeMD, Inc.$147.8M
30
OPRXOptimizeRx Corp.$149.3M
83
HCATHealth Catalyst, Inc.$127.2M
48
AMWLAmerican Well Corp.$212.4M
81
SPOKSpok Holdings, Inc.$217.5M
60
CCLDCareCloud, Inc.$95.2M
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Definitive Healthcare Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DH news & analysis

Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International

GlobeNewsWire · 2 Sept 2026neutral

Definitive Healthcare Corp. announced that a special committee of its board has received a non-binding indication of interest from Advent International to acquire all outstanding shares of Class A common stock and Definitive OpCo Units it does not already own, at an all-cash price of $1.02 per share, dated September 1, 2026.

Why it matters — A DH watcher would track this because a going-private proposal for all outstanding stock and units is a significant corporate transaction that could determine the company's future ownership and structure.

Definitive Healthcare Appoints Clay Ritchey as CEO

GlobeNewsWire · 2 Sept 2026positive

Definitive Healthcare Corp. announced that its Board of Directors has appointed Clay Ritchey as the Company's next Chief Executive Officer and as a member of the Board of Directors, effective September 8, 2026.

Why it matters — A new CEO appointment signals a leadership transition at Definitive Healthcare that DH watchers will want to track as it takes effect in September 2026.

Definitive Healthcare Corp. (DH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Definitive Healthcare Corp. (DH) held its Q2 2026 earnings call, and the full transcript of that call has been published by Seeking Alpha. The transcript covers the company's second-quarter fiscal 2026 results discussion.

Why it matters — DH watchers would care because the earnings call transcript provides the full management commentary on the company's Q2 2026 performance and outlook.

Definitive Healthcare Corp. (DH) Q2 Earnings Surpass Estimates

Zacks Investment Research · 10 Aug 2026positive

Definitive Healthcare Corp. (DH) reported Q2 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.07 per share in the same quarter a year ago.

Why it matters — The earnings beat the analyst consensus estimate, which is a notable data point for those tracking DH's quarterly performance, even though earnings declined year-over-year.

Definitive Healthcare Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026positive

Definitive Healthcare reported second-quarter fiscal 2026 revenue and profitability that met or exceeded its guidance ranges. Management highlighted improving retention trends and continued investment in artificial intelligence products as part of its plan to return to growth.

Why it matters — The results and management's stated focus on retention and AI investment signal the company's strategy toward returning to growth, which is relevant for DH watchers.

FAQ

Frequently asked questions about DH stock

What is the DH stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Definitive Healthcare Corp. have a median 12-month price target of $1.25, with estimates ranging from $0.7 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DH stock a buy right now?

Of the 8 analysts covering Definitive Healthcare Corp., 1 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Definitive Healthcare Corp. 79 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DH?

As at 2 Sept 2026, Definitive Healthcare Corp. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

Will DH stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +20.2% from the last close, and Ticker Nerd's factor model ranks Definitive Healthcare Corp. 79 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DH stock forecast for 2030?

No analyst covering Definitive Healthcare Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.7 to $3 over the next 12 months.

How has DH stock performed over the past year?

Definitive Healthcare Corp. returned -73.3% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Definitive Healthcare Corp. do?

Definitive Healthcare Corp. Class A Common Stock represents ownership in Definitive Healthcare Corp., a healthcare commercial intelligence company focused on software and data solutions for the healthcare industry.

What is the latest news on DH?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International". Definitive Healthcare Corp. announced that a special committee of its board has received a non-binding indication of interest from Advent International to acquire all outstanding shares of Class A common stock and Definitive OpCo Units it does not already own, at an all-cash price of $1.02 per share, dated September 1, 2026.

Company

About Definitive Healthcare Corp.

Definitive Healthcare Corp. Class A Common Stock represents ownership in Definitive Healthcare Corp., a healthcare commercial intelligence company focused on software and data solutions for the healthcare industry. Definitive Healthcare provides a cloud-based platform that organizes and analyzes information on healthcare providers, organizations, and related activities to support sales, marketing, clinical research, product development, and strategic planning. Its services are used by biopharmaceutical companies, medical device makers, healthcare technology firms, providers, and other organizations that operate across the healthcare ecosystem. The company is headquartered in Framingham, Massachusetts, and its Class A common stock is part of the public equity market used by investors to gain exposure to a specialized healthcare software and analytics business.

CEO Mr. Kevin D. Coop · 678 employees · United States · https://www.definitivehc.com